Strong or moderate CYP3A Inducers: Based on a dedicated drug-interaction trial in healthy subjects (N=24), concomitant rifampin (a strong CYP3A4 inducer) decreased the Cmax and AUC of neratinib by 76% and 87%, respectively, when compared to neratinib given alone. The concomitant use of strong or moderate CYP3A4 inducers should be avoided.